GEA
CELU icon

Glen Eagle Advisors’s Celularity CELU Stock Holding History

Glen Eagle Advisors’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12
Closed -$62 – 1035
2023
Q2 		$62 Hold
12
– – ﹤0.01% 1049
2023
Q1 		$71 Hold
12
– – ﹤0.01% 1058
2022
Q4 		$148 Hold
12
– – ﹤0.01% 1124
2022
Q3 		$266 Hold
12
– – ﹤0.01% 1047
2022
Q2 		$391 Buy
+12
New +$975 ﹤0.01% 955

Other funds holding CELU

SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
CVSC
C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFO
Biltmore Family Office Charlotte, North Carolina $761M AUM 31.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Glen Eagle Advisors's CELU Position: Q3 2023 in Review

Glen Eagle Advisors sold out of Celularity (CELU) in Q3 2023, closing a stake of 12 shares — an estimated $62 sold.

Glen Eagle Advisors first reported a position in CELU in Q2 2022 and held it in 5 quarters. The position peaked at $391 in Q2 2022. 45 funds tracked by Wall St. Rank hold CELU as of Q3 2023.

  • Glen Eagle Advisors reported no remaining Celularity position as of Q3 2023 after selling out during the quarter.
  • Glen Eagle Advisors sold 12 Celularity shares in Q3 2023, an estimated $62.
  • Glen Eagle Advisors first reported a position in Celularity in Q2 2022 and held it in 5 quarters.
  • Glen Eagle Advisors's Celularity position peaked at $391 in Q2 2022.
  • 45 funds tracked by Wall St. Rank held Celularity as of Q3 2023.

Based on Glen Eagle Advisors's 13F filing for Q3 2023, filed 13 Aug 2024.